Sofinnova Investments’s Roivant Sciences ROIV Stock Holding History

Sofinnova Investments’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,000,000	Closed	-$11.3M	–	71
2025 Q2	$11.3M	Buy	+1,000,000	New	+$10.8M	0.69%	38

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Sofinnova Investments's ROIV Position: Q2 2026 in Review

Sofinnova Investments sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 477,995 shares — an estimated $13.2M sold.

Sofinnova Investments first reported a position in ROIV in Q1 2024 and held it in 7 quarters. The position peaked at $47.6M in Q3 2025. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Sofinnova Investments reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
Sofinnova Investments sold 477,995 Roivant Sciences shares in Q2 2026, an estimated $13.2M.
Sofinnova Investments first reported a position in Roivant Sciences in Q1 2024 and held it in 7 quarters.
Sofinnova Investments's Roivant Sciences position peaked at $47.6M in Q3 2025.
499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.